Risk of Termination or Unfavorable Amendments to iPS Cell-Related Patent License Agreements
First written in FY2017. 4 of 5 entries say "Restated". Latest entry: FY2026.
The whole theme swung hardest in 2020: 8 of 42 companies on the "Worse" side.
50 other companies' latest entry also says "Restated".
- FY2026RestatedAnnual report
「If the agreement expires, is terminated or otherwise ends, if it is amended on terms unfavorable to us, or if the counterparty’s financial condition deteriorates or its management policy changes, this may affect our business strategy and operating performance.」
The company has reaffirmed the risks arising from termination or adverse amendment of iPS cell-related patent license agreements and changes in the counterparty’s circumstances. - FY2021RestatedAnnual report
「If the agreement expires, is terminated or otherwise ends, if it is amended on terms unfavorable to us, or if the counterparty’s financial condition deteriorates or its management policy changes, this may affect our business strategy and operating performance.」
The company has reaffirmed the risks arising from termination or adverse amendment of iPS cell-related patent license agreements and changes in the counterparty’s circumstances. - FY2020RestatedAnnual report
「If the agreement expires, is terminated or otherwise ends, if it is amended on terms unfavorable to us, or if the counterparty’s financial condition deteriorates or its management policy changes, this may affect our business strategy and operating performance.」
The company has reaffirmed the risks arising from termination or adverse amendment of iPS cell-related patent license agreements and changes in the counterparty’s circumstances. - FY2018RestatedAnnual report
「If the agreement expires, is terminated or otherwise ends, if it is amended on terms unfavorable to us, or if the counterparty’s financial condition deteriorates or its management policy changes, this may affect our business strategy and operating performance.」
The company has restated the risks associated with termination or adverse amendment of iPS cell-related patent license agreements and changes in the counterparty’s circumstances. - FY2017First statedAnnual report
「If the agreement expires, is terminated or otherwise ends, if it is amended on terms unfavorable to us, or if the counterparty’s financial condition deteriorates or its management policy changes, this may affect our business strategy and operating performance.」
The company first explicitly stated the risk of dependence on patent license agreements for the iPS cell business for which it holds licenses.